High dose intravenous immunoglobulin in autoimmune rheumatic disorders

BioDrugs

Volumn 8, Issue 5, 1997, Pages 371-386

  Zeuner, Rainald A ^a   Euler, Hans H ^a   Schroeder, Johann O ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIIDIOTYPIC ANTIBODY; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; SUPERANTIGEN;

ANTIPHOSPHOLIPID SYNDROME; ASEPTIC MENINGITIS; AUTOIMMUNITY; CELL PROLIFERATION; DRUG MEGADOSE; HEADACHE; HEMOLYSIS; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY INJURY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOPATHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RETICULOENDOTHELIAL SYSTEM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA;

EID: 0030693263     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708050-00005     Document Type: Review

References (198)

1. Schmidt RE, Budde U, Schäfer G, et al. High dose intravenous gamma globulin for idiopathic thrombocytopenic purpura. Lancet 1981; II: 475-6
2. Imbach P, Baradun S, d'Apuzzo V. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31
3. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994; 97 Suppl. 1: 49-51
4. van der Meche FG, Schmitz PI. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9
5. van Doorn PA. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1994; 57 Suppl.: 38-42
6. Tuohy PG. Intravenous immunoglobulin in chronic relapsing polyneuropathy. NZ Med J 1992; 105: 60-1
7. Churchyard A, Day T, Grainger K, et al. Intravenous immunoglobulin therapy in the inflammatory neuropathies. Clin Exp Neurol 1991; 28: 168-79
8. Levine DS, Fischer SH, Christie DL, et al. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992; 87: 91-100
9. van der Meche FG. Intravenous immune globulin in the Guillain-Barré syndrome. Clin Exp Immunol 1994; 97 Suppl. 1: 43-7
10. Kawasaki T. Kawasaki disease. Acta Paediatr 1995; 84: 713-5
11. Shulman ST. IVGG therapy in Kawasaki disease: mechanism(s) of action. Clin Immunol Immunopathol 1989; 53: S141-6
12. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000
13. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459-75
14. Romer J, Morgenthaler JJ, Scherz R, et al. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 1982; 42: 62-73
15. Romer J, Spath PJ, Skvaril F, et al. Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang 1982; 42: 74-80
16. Uemura Y, Yang YH, Heldebrant CM, et al. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994; 67: 246-54
17. Zuhrie SR, Webster AD, Davies R, et al. A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin. Clin Exp Immunol 1995; 99: 10-5
18. Hellstern P. Clinical experience with the viral safety of immunoglobulins. Blood Coagul Fibrinolysis 1994; 5 Suppl. 3: S31-4
19. Kempf C, Jentsch P, Barre-Sinoussi F, et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991; 31: 423-7
20. Morell A, Schurch B, Ryser D, et al. In vivo behaviour of gamma globulin preparations. Vox Sang 1980; 38: 272-83
21. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683-9
22. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110
23. Fischer SH, Ochs HD, Wedgwood RJ, et al. Survival of antigen-specific antibody following administration of intravenous immunoglobulin in patients with primary immunodeficiency diseases. Monogr Allergy 1988; 23: 225-35
24. Rand KH, Gibbs K, Derendorf H, et al. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 1991; 31: 1151-4
25. Skvaril F, Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 1988; 7 Suppl.: S43-8
26. Theobald K, Hogy B. Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin. Vox Sang 1995; 68: 5-8
27. Tumiati B, Casoli P, Veneziani M, et al. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 1126-33
28. Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 1994; 97 Suppl. 1: 11-5
29. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97 Suppl. 1: 79-83
30. Yanagawa H, Nakamura Y, Yashiro M. A nationwide incidence survey of Kawasaki disease 1985-1986 in Japan. J Infect Dis 1988; 158: 1296-301
31. Schiller B, Fasth A, Bjorkhem G, et al. Kawasaki disease in Sweden: incidence and clinical features. Acta Paediatr 1995; 84: 769-74
32. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and rheumatic fever. J Pediatr 1991; 119: 279-82
33. Leung DY, Meissner HC, Fulton DR, et al. Superantigens in Kawasaki syndrome. Clin Immunol Immunopathol 1995; 77: 119-26
34. Furusho K, Kamiya T, Nakano H. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-8
35. Leung DY. Kawasaki disease. Curr Opin Rheumatol 1993; 5: 41-50
36. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7
37. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a metaanalysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-61
38. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21; 1855-9
39. Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992; 326: 363-7
40. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 1994; 6: 595-601
41. Bunch TW. Azathioprine with prednisone for polymyositis. Arthritis Rheum 1981; 25: 45-8
42. Roifman CM, Schaffer FM, Wachsmuth SE, et al. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513-5
43. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-8
44. Barron KS, Sher MR, Silverman ED. Intravenous immunoglobulin therapy: magic or black magic. J Rheumatol 1992; 33 Suppl.: 94-7
45. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis: four-year review of nine cases. Arch Dis Child 1995; 72: 25-8
46. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35
47. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994; 21: 1092-7
48. Stoll T, Michel BA, Neidhart M, et al. Polymyositis: diseasecourse and therapy With intravenously administered immunoglobulins [in German]. Schweiz Med Wochenschr 1992; 122: 1458-65
49. Kaye SA, Isenberg DA. Treatment of polymyositis and dermatomyositis. Br J Hosp Med 1994; 52: 463-8
50. Soueidan SA, Dalakas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876-9
51. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44: 1516-8
52. Salvarani C, Boiardi L, Maldini MC, et al. High dose immunoglobulin therapy in a case of inclusion body myositis: clinical and immunologic aspects. J Rheumatol 1993; 20: 1455-6
53. Abu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-64
54. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995; 38: 274-83
55. Klippel JH, Survival in SLE. Proc Int Conf SLE 1990; 2: 187-9
56. Klippel JH. Immune suppression in the treatment of SLE. Proc Int Conf SLE 1989; 2: 200-2
57. Austin HA, Klippel JH, Balow JE. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
58. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4
59. Felson DT, Andersson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984; 311: 1528-33
60. Gaedicke G, Teller WM, Kohne E, et al. IgG therapy in systemic lupus erythematosus: two case reports. Blut 1984; 48: 387-90
61. Lin RY, Racis SP. In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration. Int Arch Allergy Appl Immunol 1986; 79: 286-90
62. Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 1990; 33: 1233-9
63. Akashi K, Nagasawa K, Mayumi T, et al. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 1990; 17: 375-9
64. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 163-8
65. Roldan R, Roman J, Lopez D, et al. Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methyl-prednisolone and intravenous immunoglobulins in SLE. Scand J Rheumatol 1994; 23: 218-9
66. Cohen MG, Li EK. Limited effects of intravenous IgG in treating systemic lupus erythematosus-associated thrombocytopenia [letter]. Arthritis Rheum 1991; 34: 787-8
67. ter Borg EJ, Kallenberg CGM. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous immunoglobulin. Ann Rheum Dis 1992; 51: 1149-51
68. Becker BN, Fuchs H, Hakim R. Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol 1995; 5: 1746-50
69. Sturfelt G, Mousa F, Jonsson H, et al. Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 939-41
70. Winder A, Molad Y, Ostfeld I, et al. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993; 20: 495-8
71. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989; 53: 303-10
72. Schroeder JO, Zeuner RA, Euler HH, et al. High dose intravenous immunoglobulins in SLE: clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71-5
73. Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989; 7: 295-9
74. Pasatiempo AM, Kroser JA, Rudnick M, et al. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347-9
75. Schifferli JA, Leski M, Favre H, et al. High-dose intravenous IgG treatment and renal function. Lancet 1991; 337: 457-8
76. Pirner K, Rubbert A, Burmester GR, et al. Intravenös verabreichte Immunglobuline beim SLE: Literaturübersicht und erste klinische Erfahrungen. Infusionsther Transfusionsmed 1993; 20: 131-6
77. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-34
78. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993; 50: 137-9
79. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18
80. Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anti-cardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48: 362-7
81. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4
82. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7
83. Spinnato JA, Clark AL, Pierangeli SS, et al. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995; 172: 690-4
84. Arnout J, Spitz B, Wittevrongel C, et al. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994; 71: 741-7
85. Kaaja R, Julkunen H, Ammala P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993; 72: 63-6
86. Hudak CD, Spiridonidis CH, Hart AJ, et al. Pregnancy-associated factor VIII inhibitor: treatment with intravenous high-dose immunoglobulin. Am J Hematol 1993; 43: 158
87. Nakamura Y, Uchida Y, Murakami M. Intravenous gammaglobulin in a hypothyroid patient with the antiphospholipid antibody syndrome. Ann Intern Med 1993; 118; 827-8
88. Hanley D, Arkel YS, Lynch J, et al. Acquired von Willebrand's syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin. Am J Hematol 1994; 46: 141-6
89. Galli M, Cortelazzo S, Barbui T. In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism. Am J Hematol 1991; 38: 184-8
90. Parke A, Maier D, Wilson D, et al. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 1989; 110: 495-6
91. Matsuda J, Gohchi K, Kawasugi K, et al. In vitro lupus anticoagulant neutralizing activity of intravenous immunoglobulin. Thromb Res 1993; 70: 109-10
92. Said PB, Martinuzzo ME, Carreras LO. Neutralization of lupus anticoagulant activity by human immunoglobulin 'in vitro'. Nouv Rev Fr Hematol 1992; 34: 37-42
93. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-6
94. Hadi HA. Intravenous immunoglobulin therapy for recurrent abortion: 'state of the art' or 'experimental therapy'? Fertil Steril 1992; 58: 451-2
95. Orvieto R, Achiron A, Ben-Rafael Z, et al. Intravenous immunoglobulin treatment for recurrent abortions caused by antiphospholipid antibodies. Fertil Steril 1991; 56: 1013-20
96. Buyon JP, Yaron M, Lockshin MD. First International Conference on Rheumatic Disease in Pregnancy. Arthritis Rheum 1993; 36: 59-64
97. Athreya BH, Cassidy JT. Current status of the medical treatment of children with juvenile rheumatoid arthritis. Rheum Dis Clin North Am 1991; 17: 871-89
98. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991; 17: 891-905
99. Falcini F, Taccetti G, Trapani S, et al. Growth retardation in juvenile chronic arthritis patients treated with steroids. Clin Exp Rheumatol 1991; 9 Suppl. 6: 37-40
100. Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 1990; 8: 603-8
101. Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarthricular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 1996; 23: 919-24
102. Groothoff JW, van Leeuwen EF. High dose intravenous immunoglobulin in chronic systemic juvenile arthritis. BMJ 1992; 296: 1362-3
103. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015-22
104. Uziel Y, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 910-8
105. Silverman ED, Cawkwell GD, Lovell DJ, Pediatric Rheumatology Collaborative Study Group, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo-controlled trial. J Rheumatol 1994; 21: 2353-8
106. Emery P, Spath P, Affentranger P, et al. A placebo-controlled double-blind study of high dose intravenous immunoglobulin therapy in patients with early rheumatoid arthritis. Arthritis Rheum 1993; 36: S57
107. Muscat C, Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 1995; 54: 382-5
108. Savery F. Intravenous immunoglobulin treatment of rheumatoid arthritis-associated immunodeficiency. Clin Ther 1988; 10: 527-9
109. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
110. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98
111. Jayne DR, Davies MJ, Fox CJV, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137-9
112. Boman S, Ballen JL, Seggev JS. Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 1995; 238: 375-7
113. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207-19
114. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993; 336: 469-72
115. Richter C, Schnabel A, Csernok E, et al. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993; 336: 487-9
116. Tuso P, Moudgil A, Hay J, et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 1992; 20: 504-8
117. Rossi F, Jayne DR, Lockwood CM, et al. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83: 298-303
118. Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101: 2-7
119. Finkel TH, Torok TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343: 1255-8
120. Zeuner RA, Schroeder JO, Schroder F, et al. Successful application of high dose intravenous immunoglobulins in Sjogren's syndrome associated arthritis. Ann Rheum Dis 1995; 54: 936
121. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77: 2010-8
122. Burdach SE, Evers KG, Geursen RG. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: comparative efficacy of 7S and 5S preparations. J Pediatr 1986; 109: 770-5
123. Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody. N Engl J Med 1986; 314: 1236-9
124. Fehr J, Hofmann V, Kappeler V. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high dose gamma globulin. N Engl J Med 1982; 306 (21): 1254-8
125. Newland AC, Macey MG. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994; 69: 61-7
126. Sheth KV, al-Sedairy S, Lee J. Effectiveness of four intravenous IgG preparations in prevention of phagocytosis of anti-Rh-(D)-coated erythrocytes by mononuclear phagocytes. Vox Sang 1993; 65: 190-3
127. Debré M, Bonnet MC, Fridman WH, et al. Infusion of Fc-gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945-9
128. Basta M, Fries LF, Frank M. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitised erythrocytes. Blood 1991; 77: 376-80
129. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62: S82-6
130. a-IgG complexes. Blood 1996; 88: 184-93
131. Basta M, Fries LF, Frank MM. High-doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood 1991; 78: 700-2
132. Qi M, Schifferli JA. Inhibition of complement activation by intravenous immunoglobulins. Arthritis Rheum 1995; 38: 146
133. Mollnes TE, Hogasen K, Hoaas BF, et al. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand J Immunol 1995; 41: 449-56
134. Zeuner RA, Schroeder JO, Euler HH. Transient reduction of complement C3 and C4 levels after high-dose intravenous immunoglobulin treatment in collagen vascular disorders. Mol Immunol 1996; 33: 28
135. Zeuner RA, Beréss R, Euler HH, et al. Reduction of complement-mediated inhibition of immune precipitation (CMIIP) by high-dose intravenous immunoglobulin (IVIG). Immmunobiology 1996; 196: 287
136. Gautreau C, Kojima T, Woimant G, et al. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection: an in vivo and in vitro evaluation. Transplantation 1995; 60: 903-7
137. Gautreau C, Cardoso J, Woimant G, et al. Prevention of hyperacute xenograft rejection by intravenous immunoglobulin in the pig-to-human combination. Transplant Proc 1994; 26: 1281
138. Euler HH, Schroeder JO. Dermatomyositis and systemic lupus erythematosus. In: Kazatchkine MD, editor. Intravenous immunoglobulin therapy. Pearl River (NY): Parthenon Publishing Group, 1995: 53-7
139. Nydegger UE, Sultan Y, Kazatchkine MD. The concept of antiidiotypic regulation of selected autoimmune diseases by intravenous immunoglobulin. Clin Immunol Immunopathol 1989; 53: 72-82
140. Sultan Y, Kazatchkine MD, Nydegger U, et al. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991; 91: 35S-9S
141. Sultan Y, Kazatchkine MD, Maisoneuve P, et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high dose intravenous gammaglobulin. Lancet 1984; II: 765-8
142. Kotzin BL, Leung DY, Kappler J, et al. Superantigens and their potential role in human disease. Adv Immunol 1993; 54: 99-166
143. Lekova ES, Joffe L, Glode MP. Antigenic recognition by intravenous gamma-globulin of selected bacteria isolated from throats of patients with Kawasaki syndrome. Pediatr Infect Dis J 1990; 9: 620-3
144. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 602-7
145. Skansen-Saphir U, Andersson J, Bjork L, et al. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 1994; 24: 916-22
146. Leung DY, Giorno RC, Kazemi LV, et al. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995; 155: 5018-21
147. Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385-8
148. Leung DY, The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases. Clin Rev Allergy 1992; 10: 93-104
149. Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178-89
150. Amran D, Renz, H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73: 180-6
151. Sbrana S, Ruocco L, Vanacore R, et al. In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T-cells activation. Allerg Immunol (Paris) 1993; 25: 35-7
152. Kondo N, Kasahara K, Kameyama T, et al. Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol 1994; 40: 37-42
153. van Schaik IN, Lundkvist I, Vermeulen M, et al. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12: 325-34
154. Ruiz de Souza V, Carreno MP, Kaveri SV, et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995; 25: 1267-73
155. Darville T, Tabor D, Simpson K, et al. Intravenous immunoglobulin modulates human mononuclear phagocyte tumor necrosis factor-alpha production in vitro. Pediatr Res 1994; 35: 397-403
156. Oravec S, Ronda N, Carayon A, et al. Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro. Nephrol Dial Transplant 1995; 10: 796-800
157. Arend WP, Leung DY, IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 1994; 139: 71-8
158. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136-43
159. Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells (Dayt) 1995; 13: 206-22
160. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol 1993; 20: 2176-7
161. ASHP Commission on Therapeutics. Summary of the ASHP therapeutic guidelines for intravenous immune globulin. Am J Hosp Pharm 1992; 49: 652-4
162. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993; 9: 254-62
163. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993; 78: 35-40
164. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989-95
165. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-62
166. Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988; 259: 3269-71
167. Ahsan N, Palmer BF, Wheeler D, et al. Intravenous imnunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994; 154: 1985-7
168. Ruggeri M, Castaman G, De Nardi G, et al. Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. Haematologica 1993; 78: 338-9
169. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-4
170. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994; 44: 1180-1
171. Woodruff RK, Griff AP, Firkin FL, et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulins in elderly patients. Lancet 1986; 11: 217-8
172. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulins. Lancet 1986; II: 468
173. Thomas MJ, Misbah SA, Chapel HM, et al. Hemolysis after high-dose intravenous Ig. Blood 1993; 82: 3789
174. Comenzo RL, Malachowski ME, Meissner HC. et al. Immune hemolysis. disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120: 926-8
175. Nakamura S, Yoshida T, Ohtake S, et al. Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol 1986; 76: 115-8
176. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992; 326: 270-1
177. Potter M, Stockley R, Storry J, et al. ABO alloimmunisation after intravenous immunoglobulin infusion. Lancet 1988; I: 932-3
178. Valensise H, Vaquero E, De Carolis C, et al. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenal Diagn 1995; 15: 509-17
179. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum 1995; 38: 1722-32
180. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline development by explicit methods for The American Society of Hematology. Blood 1996; 88: 3-40
181. Koskinen S, Tolo H, Hirvonen M, et al. Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults. J Clin Immunol 1995; 15: 194-8
182. McCluskey DR, Boyd NA. Anaphylaxis with intravenous gammaglobulin. Lancet 1990; 336: 874
183. Ferreira A, Garcia Rodriguez MC, Fontan G. Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with gamma-globulin. Vox Sang 1989; 56: 218-22
184. Ferreira A, Garcia Rodriguez MC, Lopez-Trascasa M, et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 1988; 47: 199-207
185. Deicher H, Peter HH. Humane Immunglobuline. In: Vorstand und wissenschaftlicher Beirat der Bundesärztekammer. editor. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzte Verlag 1995: 139-62
186. Cunningham-Rundles C, Zhou Z, Mankarious S, et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272-8
187. Björkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG sub-class deficiency. Am J Med 1988; 84: 107-11
188. Lane RS, Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet 1983; II: 974-5
189. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994; 331: 1649-50
190. Yap PL, McOmish F, Webster AD, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994; 21: 455-60
191. Centers for Disease Control and Prevention. Outbreak of hepatitis C associated with intravenous immunoglobulin administration: United States, October 1993-June 1994. JAMA 1994; 272: 424-5
192. Lehner PS, Webster AD. Hepatitis C from immunoglobin infusions. BMJ 1993; 306: 1541-2
193. Webster AD. Intravenous immunoglobulins. BMJ 1991; 303: 375-6
194. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11
195. Anonymous. Non-A, non-B hepatitis after intravenous gamma-globulin. Lancet 1986; 1: 322-3
196. Williams PE, Yap PL, Gillon J, et al. Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulins. Vox Sang 1989; 57: 15-8
197. Ebeling F, Baer M, Hormila P, et al. Tolerability and kinetics of a solvent detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients. Vox Sang 1995; 69: 91-4
198. Hamamoto Y, Harada S, Yamamoto N, et al. Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation. Vox Sang 1987; 53: 65-9